Skip to main content
PMC home page
Springer logoLink to Springer
. 2024 Sep 20;31(6):1184. doi: 10.1007/s12282-024-01632-z

Correction: Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)

Takahiro Nakayama 1, Naoki Niikura 2,✉, Takashi Yamanaka 3, Mitsugu Yamamoto 4, Kazuo Matsuura 5, Kenichi Inoue 6, Sachiko Takahara 7, Hironori Nomura 8, Shosuke Kita 9, Miki Yamaguchi 10, Tomoyuki Aruga 11, Nobuhiro Shibata 12, Akihiko Shimomura 13, Yuri Ozaki 14, Shuji Sakai 15, Daisuke Takiguchi 16, Takehiko Takata 16, Armin Bastanfard 16, Kazuhito Shiosakai 17, Junji Tsurutani 18
PMCID: PMC11489219  PMID: 39302559

Correction: Breast Cancer 10.1007/s12282-024-01614-1

In Table 2 of this article, the number of cases, ‘N = 114’ in the column head “Updated results; …” should have read ‘N = 104’.

The original article has been corrected.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Articles from Breast Cancer (Tokyo, Japan) are provided here courtesy of Springer

RESOURCES